Later, it was shown that MPN driver mutations, such as JAK2V617F and MPL, were responsible for continuous, increased signaling via the JAK2-STAT pathway and the promotion of cytokine production by malignant and non-malignant cells [58–61]. Here, JAK2 is linked to myeloproliferative disorder.